Global Vaccine Adjuvants Sales 麻豆原创 Report 2023

Publication ID:

PB501232350

Publication Date:

January 2, 2023

Pages:

137

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,000.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years. And many vaccines also contain an adjuvant or adjuvant combination: these are substances added to vaccines specifically because of their immune enhancing effects. Adjuvants were initially used to counter the poor immunogenic potential of highly purified antigens. In recent years their role has expanded as our understanding of the immunology of vaccination has grown.
麻豆原创 Analysis and Insights: Global Vaccine Adjuvants 麻豆原创
Due to the COVID-19 pandemic, the global Vaccine Adjuvants market size is estimated to be worth US$ 852.8 million in 2022 and is forecast to a readjusted size of US$ 1569.9 million by 2029 with a CAGR of 9.0% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, Aluminum Adjuvant accounting for % of the Vaccine Adjuvants global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Human Vaccine segment is altered to an % CAGR throughout this forecast period.
The top 5 global manufacturers of vaccine adjuvants are GSK, CSL Limited, Croda, SEPPIC, Novavax, which have a combined market share of about 55 percent. North America is the largest market, with a share about 38%, followed by Europe and Asia Pacific with the share about 27% and 22%.
Global Vaccine Adjuvants Scope and 麻豆原创 Size
The global Vaccine Adjuvants market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Vaccine Adjuvants market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2029.
Segment by Type
Aluminum Adjuvant
Emulsions Adjuvant
Others
Segment by Application
Human Vaccine
Veterinary Vaccine
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
GSK
CSL Limited
Croda
SEPPIC
Novavax
SPI Pharma
Phibro
SDA BIO
Invivogen
Tj Kaiwei
OZ Biosciences
Brenntag Biosector
MVP Laboratories
Zhuoyue
Aphios

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Vaccine Adjuvants 麻豆原创 Overview
1.1 Vaccine Adjuvants Product Scope
1.2 Vaccine Adjuvants Segment by Type
1.2.1 Global Vaccine Adjuvants Sales by Type (2018 & 2022 & 2029)
1.2.2 Aluminum Adjuvant
1.2.3 Emulsions Adjuvant
1.2.4 Others
1.3 Vaccine Adjuvants Segment by Application
1.3.1 Global Vaccine Adjuvants Sales Comparison by Application (2018 & 2022 & 2029)
1.3.2 Human Vaccine
1.3.3 Veterinary Vaccine
1.4 Vaccine Adjuvants 麻豆原创 Estimates and Forecasts (2018-2029)
1.4.1 Global Vaccine Adjuvants 麻豆原创 Size in Value Growth Rate (2018-2029)
1.4.2 Global Vaccine Adjuvants 麻豆原创 Size in Volume Growth Rate (2018-2029)
1.4.3 Global Vaccine Adjuvants Price Trends (2018-2029)
2 Vaccine Adjuvants Estimates and Forecasts by Region
2.1 Global Vaccine Adjuvants 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2 Global Vaccine Adjuvants Retrospective 麻豆原创 Scenario by Region (2018-2023)
2.2.1 Global Vaccine Adjuvants Sales 麻豆原创 Share by Region (2018-2023)
2.2.2 Global Vaccine Adjuvants Revenue 麻豆原创 Share by Region (2018-2023)
2.3 Global Vaccine Adjuvants 麻豆原创 Estimates and Forecasts by Region (2024-2029)
2.3.1 Global Vaccine Adjuvants Sales Estimates and Forecasts by Region (2024-2029)
2.3.2 Global Vaccine Adjuvants Revenue Forecast by Region (2024-2029)
2.4 Geographic 麻豆原创 Analysis: 麻豆原创 Facts & Figures
2.4.1 United States Vaccine Adjuvants Estimates and Projections (2018-2029)
2.4.2 Europe Vaccine Adjuvants Estimates and Projections (2018-2029)
2.4.3 China Vaccine Adjuvants Estimates and Projections (2018-2029)
2.4.4 Japan Vaccine Adjuvants Estimates and Projections (2018-2029)
2.4.5 Southeast Asia Vaccine Adjuvants Estimates and Projections (2018-2029)
2.4.6 India Vaccine Adjuvants Estimates and Projections (2018-2029)
3 Global Vaccine Adjuvants Competition Landscape by Players
3.1 Global Top Vaccine Adjuvants Players by Sales (2018-2023)
3.2 Global Top Vaccine Adjuvants Players by Revenue (2018-2023)
3.3 Global Vaccine Adjuvants 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Vaccine Adjuvants as of 2022)
3.4 Global Vaccine Adjuvants Average Price by Company (2018-2023)
3.5 Manufacturers Vaccine Adjuvants Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Vaccine Adjuvants 麻豆原创 Size by Type
4.1 Global Vaccine Adjuvants Historic 麻豆原创 Review by Type (2018-2023)
4.1.1 Global Vaccine Adjuvants Sales by Type (2018-2023)
4.1.2 Global Vaccine Adjuvants Revenue by Type (2018-2023)
4.1.3 Global Vaccine Adjuvants Price by Type (2018-2023)
4.2 Global Vaccine Adjuvants 麻豆原创 Estimates and Forecasts by Type (2024-2029)
4.2.1 Global Vaccine Adjuvants Sales Forecast by Type (2024-2029)
4.2.2 Global Vaccine Adjuvants Revenue Forecast by Type (2024-2029)
4.2.3 Global Vaccine Adjuvants Price Forecast by Type (2024-2029)
5 Global Vaccine Adjuvants 麻豆原创 Size by Application
5.1 Global Vaccine Adjuvants Historic 麻豆原创 Review by Application (2018-2023)
5.1.1 Global Vaccine Adjuvants Sales by Application (2018-2023)
5.1.2 Global Vaccine Adjuvants Revenue by Application (2018-2023)
5.1.3 Global Vaccine Adjuvants Price by Application (2018-2023)
5.2 Global Vaccine Adjuvants 麻豆原创 Estimates and Forecasts by Application (2024-2029)
5.2.1 Global Vaccine Adjuvants Sales Forecast by Application (2024-2029)
5.2.2 Global Vaccine Adjuvants Revenue Forecast by Application (2024-2029)
5.2.3 Global Vaccine Adjuvants Price Forecast by Application (2024-2029)
6 United States Vaccine Adjuvants 麻豆原创 Facts & Figures
6.1 United States Vaccine Adjuvants Sales by Company
6.1.1 United States Vaccine Adjuvants Sales by Company (2018-2023)
6.1.2 United States Vaccine Adjuvants Revenue by Company (2018-2023)
6.2 United States Vaccine Adjuvants Sales Breakdown by Type
6.2.1 United States Vaccine Adjuvants Sales Breakdown by Type (2018-2023)
6.2.2 United States Vaccine Adjuvants Sales Breakdown by Type (2024-2029)
6.3 United States Vaccine Adjuvants Sales Breakdown by Application
6.3.1 United States Vaccine Adjuvants Sales Breakdown by Application (2018-2023)
6.3.2 United States Vaccine Adjuvants Sales Breakdown by Application (2024-2029)
7 Europe Vaccine Adjuvants 麻豆原创 Facts & Figures
7.1 Europe Vaccine Adjuvants Sales by Company
7.1.1 Europe Vaccine Adjuvants Sales by Company (2018-2023)
7.1.2 Europe Vaccine Adjuvants Revenue by Company (2018-2023)
7.2 Europe Vaccine Adjuvants Sales Breakdown by Type
7.2.1 Europe Vaccine Adjuvants Sales Breakdown by Type (2018-2023)
7.2.2 Europe Vaccine Adjuvants Sales Breakdown by Type (2024-2029)
7.3 Europe Vaccine Adjuvants Sales Breakdown by Application
7.3.1 Europe Vaccine Adjuvants Sales Breakdown by Application (2018-2023)
7.3.2 Europe Vaccine Adjuvants Sales Breakdown by Application (2024-2029)
8 China Vaccine Adjuvants 麻豆原创 Facts & Figures
8.1 China Vaccine Adjuvants Sales by Company
8.1.1 China Vaccine Adjuvants Sales by Company (2018-2023)
8.1.2 China Vaccine Adjuvants Revenue by Company (2018-2023)
8.2 China Vaccine Adjuvants Sales Breakdown by Type
8.2.1 China Vaccine Adjuvants Sales Breakdown by Type (2018-2023)
8.2.2 China Vaccine Adjuvants Sales Breakdown by Type (2024-2029)
8.3 China Vaccine Adjuvants Sales Breakdown by Application
8.3.1 China Vaccine Adjuvants Sales Breakdown by Application (2018-2023)
8.3.2 China Vaccine Adjuvants Sales Breakdown by Application (2024-2029)
9 Japan Vaccine Adjuvants 麻豆原创 Facts & Figures
9.1 Japan Vaccine Adjuvants Sales by Company
9.1.1 Japan Vaccine Adjuvants Sales by Company (2018-2023)
9.1.2 Japan Vaccine Adjuvants Revenue by Company (2018-2023)
9.2 Japan Vaccine Adjuvants Sales Breakdown by Type
9.2.1 Japan Vaccine Adjuvants Sales Breakdown by Type (2018-2023)
9.2.2 Japan Vaccine Adjuvants Sales Breakdown by Type (2024-2029)
9.3 Japan Vaccine Adjuvants Sales Breakdown by Application
9.3.1 Japan Vaccine Adjuvants Sales Breakdown by Application (2018-2023)
9.3.2 Japan Vaccine Adjuvants Sales Breakdown by Application (2024-2029)
10 Southeast Asia Vaccine Adjuvants 麻豆原创 Facts & Figures
10.1 Southeast Asia Vaccine Adjuvants Sales by Company
10.1.1 Southeast Asia Vaccine Adjuvants Sales by Company (2018-2023)
10.1.2 Southeast Asia Vaccine Adjuvants Revenue by Company (2018-2023)
10.2 Southeast Asia Vaccine Adjuvants Sales Breakdown by Type
10.2.1 Southeast Asia Vaccine Adjuvants Sales Breakdown by Type (2018-2023)
10.2.2 Southeast Asia Vaccine Adjuvants Sales Breakdown by Type (2024-2029)
10.3 Southeast Asia Vaccine Adjuvants Sales Breakdown by Application
10.3.1 Southeast Asia Vaccine Adjuvants Sales Breakdown by Application (2018-2023)
10.3.2 Southeast Asia Vaccine Adjuvants Sales Breakdown by Application (2024-2029)
11 India Vaccine Adjuvants 麻豆原创 Facts & Figures
11.1 India Vaccine Adjuvants Sales by Company
11.1.1 India Vaccine Adjuvants Sales by Company (2018-2023)
11.1.2 India Vaccine Adjuvants Revenue by Company (2018-2023)
11.2 India Vaccine Adjuvants Sales Breakdown by Type
11.2.1 India Vaccine Adjuvants Sales Breakdown by Type (2018-2023)
11.2.2 India Vaccine Adjuvants Sales Breakdown by Type (2024-2029)
11.3 India Vaccine Adjuvants Sales Breakdown by Application
11.3.1 India Vaccine Adjuvants Sales Breakdown by Application (2018-2023)
11.3.2 India Vaccine Adjuvants Sales Breakdown by Application (2024-2029)
12 Company Profiles and Key Figures in Vaccine Adjuvants Business
12.1 GSK
12.1.1 GSK Corporation Information
12.1.2 GSK Business Overview
12.1.3 GSK Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.1.4 GSK Vaccine Adjuvants Products Offered
12.1.5 GSK Recent Development
12.2 CSL Limited
12.2.1 CSL Limited Corporation Information
12.2.2 CSL Limited Business Overview
12.2.3 CSL Limited Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.2.4 CSL Limited Vaccine Adjuvants Products Offered
12.2.5 CSL Limited Recent Development
12.3 Croda
12.3.1 Croda Corporation Information
12.3.2 Croda Business Overview
12.3.3 Croda Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.3.4 Croda Vaccine Adjuvants Products Offered
12.3.5 Croda Recent Development
12.4 SEPPIC
12.4.1 SEPPIC Corporation Information
12.4.2 SEPPIC Business Overview
12.4.3 SEPPIC Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.4.4 SEPPIC Vaccine Adjuvants Products Offered
12.4.5 SEPPIC Recent Development
12.5 Novavax
12.5.1 Novavax Corporation Information
12.5.2 Novavax Business Overview
12.5.3 Novavax Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.5.4 Novavax Vaccine Adjuvants Products Offered
12.5.5 Novavax Recent Development
12.6 SPI Pharma
12.6.1 SPI Pharma Corporation Information
12.6.2 SPI Pharma Business Overview
12.6.3 SPI Pharma Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.6.4 SPI Pharma Vaccine Adjuvants Products Offered
12.6.5 SPI Pharma Recent Development
12.7 Phibro
12.7.1 Phibro Corporation Information
12.7.2 Phibro Business Overview
12.7.3 Phibro Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.7.4 Phibro Vaccine Adjuvants Products Offered
12.7.5 Phibro Recent Development
12.8 SDA BIO
12.8.1 SDA BIO Corporation Information
12.8.2 SDA BIO Business Overview
12.8.3 SDA BIO Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.8.4 SDA BIO Vaccine Adjuvants Products Offered
12.8.5 SDA BIO Recent Development
12.9 Invivogen
12.9.1 Invivogen Corporation Information
12.9.2 Invivogen Business Overview
12.9.3 Invivogen Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.9.4 Invivogen Vaccine Adjuvants Products Offered
12.9.5 Invivogen Recent Development
12.10 Tj Kaiwei
12.10.1 Tj Kaiwei Corporation Information
12.10.2 Tj Kaiwei Business Overview
12.10.3 Tj Kaiwei Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.10.4 Tj Kaiwei Vaccine Adjuvants Products Offered
12.10.5 Tj Kaiwei Recent Development
12.11 OZ Biosciences
12.11.1 OZ Biosciences Corporation Information
12.11.2 OZ Biosciences Business Overview
12.11.3 OZ Biosciences Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.11.4 OZ Biosciences Vaccine Adjuvants Products Offered
12.11.5 OZ Biosciences Recent Development
12.12 Brenntag Biosector
12.12.1 Brenntag Biosector Corporation Information
12.12.2 Brenntag Biosector Business Overview
12.12.3 Brenntag Biosector Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.12.4 Brenntag Biosector Vaccine Adjuvants Products Offered
12.12.5 Brenntag Biosector Recent Development
12.13 MVP Laboratories
12.13.1 MVP Laboratories Corporation Information
12.13.2 MVP Laboratories Business Overview
12.13.3 MVP Laboratories Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.13.4 MVP Laboratories Vaccine Adjuvants Products Offered
12.13.5 MVP Laboratories Recent Development
12.14 Zhuoyue
12.14.1 Zhuoyue Corporation Information
12.14.2 Zhuoyue Business Overview
12.14.3 Zhuoyue Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.14.4 Zhuoyue Vaccine Adjuvants Products Offered
12.14.5 Zhuoyue Recent Development
12.15 Aphios
12.15.1 Aphios Corporation Information
12.15.2 Aphios Business Overview
12.15.3 Aphios Vaccine Adjuvants Sales, Revenue and Gross Margin (2018-2023)
12.15.4 Aphios Vaccine Adjuvants Products Offered
12.15.5 Aphios Recent Development
13 Vaccine Adjuvants Manufacturing Cost Analysis
13.1 Vaccine Adjuvants Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Vaccine Adjuvants
13.4 Vaccine Adjuvants Industrial Chain Analysis
14 麻豆原创ing Channel, Distributors and Customers
14.1 麻豆原创ing Channel
14.2 Vaccine Adjuvants Distributors List
14.3 Vaccine Adjuvants Customers
15 麻豆原创 Dynamics
15.1 Vaccine Adjuvants Industry Trends
15.2 Vaccine Adjuvants 麻豆原创 Drivers
15.3 Vaccine Adjuvants 麻豆原创 Challenges
15.4 Vaccine Adjuvants 麻豆原创 Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

Companies Mentioned:

GSK
CSL Limited
Croda
SEPPIC
Novavax
SPI Pharma
Phibro
SDA BIO
Invivogen
Tj Kaiwei
OZ Biosciences
Brenntag Biosector
MVP Laboratories
Zhuoyue
Aphios

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.